Call for Fierce 15 nominees

It's that time of year again.

The sixth annual Fierce 15, our take on a slate of the most promising private biotech companies in the world, will be coming out in June. And I'd like to know if you have any companies that you'd like me to consider.

It doesn't take much. Just a name e-mailed my way will suffice. I promise to take a look.

We've already identified a lengthy list of candidates this year, with some amazing managers, scientists and programs in the running. This is the most fun I have every year, and I'll be looking forward to seeing who you want to nominate. - John Carroll

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.